In our clinical practice, we presented a case which is very confusing: a patient that wakes up one morning with a droopy eyelid, which may be on one side of the face, and by that afternoon had improved, only to return the next day.
Also, we had patients present with double vision, which is only present when they are tired, at night time their vision is 100% normal. Ocular myasthenia gravis is a disease in which the muscles that move the eye and lift the eyelid become weak due to the breakdown of the signal at the nerve-muscle junction.
What we see is that this weakness is fluctuating in nature; it is often at its worst with activity or tiredness and improves with rest. It is not a rare disease and we have effective treatments for it. But because the symptoms come and go, diagnosis is often delayed and patients may go for weeks thinking it is just tiredness or stress.
What Is Ocular Myasthenia Gravis?
The levator muscle which raises the upper eyelid and the extraocular muscles which move the eye in different directions. In some patients, this eye involvement is the only issue for their life. In others the ocular myasthenia gravis is the first to present which then goes on to affect muscles of the face, throat, limbs and in severe cases breathing. This is why early diagnosis and close follow-up are important even when the symptoms are within the eyes.
What Causes Ocular Myasthenia Gravis?
In most cases what we see is an auto immune attack on the neuromuscular junction. In the great majority of generalized myasthenia gravis cases we find antibodies against acetylcholine receptors in the blood. In purely ocular cases these antibodies may be present at lower levels or may completely be absent which adds to the diagnostic challenge.
| Cause or associated factor | Details |
| AChR antibody production | Most common mechanism; antibodies block or destroy acetylcholine receptors at the neuromuscular junction, reducing muscle response. |
| MuSK antibodies | A smaller proportion of patients have antibodies against muscle-specific kinase (MuSK); more common in generalised disease, occasionally in ocular forms. |
| Thymus gland abnormalities | The thymus a gland in the chest is often involved in driving the autoimmune response. Thymomas or thymic hyperplasia are found in a significant proportion of generalised myasthenia gravis patients and need to be assessed at diagnosis. |
| Seronegative disease | Some patients have neither AChR nor MuSK antibodies but still have clinical and electrophysiological features consistent with myasthenia gravis. |
Myasthenia gravis can occur at any age, in both men and women. There is a slightly higher prevalence in younger women and older men, though this pattern is not absolute.
What Are the First Signs of Ocular Myasthenia?
The two most characteristic presentations are ptosis and diplopia. These can occur together or separately, and their fluctuating nature is the key clinical feature that points towards the diagnosis.
| Symptom | How patients typically describe it |
| Ptosis (drooping eyelid) | One or both eyelids gradually droop, especially in the evening or after prolonged reading or screen time; it often improves after rest or sleep. |
| Diplopia (double vision) | Objects appear doubled, especially when looking in a particular direction; it may be worse at the end of the day and absent after rest. |
| Fatigue with sustained gaze | Holding the eyes in one position such as looking up or to the side makes symptoms worse. |
| Variable asymmetry | The drooping or double vision is often asymmetric, affecting one side more than the other, and may switch sides over time. |
A useful observation we share with patients is the “ice pack test.” Applying a cold pack over the closed eye for a couple of minutes often temporarily improves ptosis in myasthenia gravis, because the neuromuscular junction works better at cooler temperatures. This simple bedside test can be strongly suggestive of the diagnosis.
How Is Ocular Myasthenia Gravis Diagnosed?
Because symptoms fluctuate and eye movement problems can have many causes, the diagnosis of ocular myasthenia requires a combination of clinical findings and investigations.
| Investigation | What it looks for |
| AChR and MuSK antibodies | Blood tests to detect the antibodies responsible for the neuromuscular attack; negative results do not fully exclude the diagnosis. |
| Repetitive nerve stimulation (RNS) | An electrophysiological test that shows a characteristic decremental response in myasthenia gravis. |
| Single-fibre EMG (SFEMG) | The most sensitive electrophysiological test for neuromuscular junction disease; can detect abnormality even when antibodies are absent. |
| Edrophonium (Tensilon) test | A short-acting drug that briefly increases acetylcholine at the junction; if ptosis improves within minutes, it supports the diagnosis. Rarely used today due to risks. |
| CT or MRI of the chest | To look for a thymoma or thymic enlargement, which must be excluded in all newly diagnosed patients. |
| Thyroid function and other autoimmune tests | Myasthenia gravis can co-exist with other autoimmune conditions including thyroid disease. |
This evaluation is typically carried out in collaboration between the ophthalmologist, neurologist and sometimes a thoracic surgeon, depending on what the chest imaging shows. A specialist eye hospital that works within a multi-disciplinary framework is best placed to coordinate this workup efficiently.
Is Ocular Myasthenia Gravis Serious?
Ocular myasthenia gravis is a real diagnosis which does play a role in quality of life. We see the drooping eyelid and double vision which in turn makes for unsafe driving, difficult reading, and daily tasks which are exhaustive. It also plays a role in how we present to the world and in turn in how we feel about ourselves, especially as the drooping is noted by others. At the same time it is important to note that while ocular myasthenia affects the eyes it does not in the great majority of cases directly attack vision or cause permanent damage to eye muscles. What we do see is a risk of this condition to progress into generalized myasthenia gravis which may include issues with swallowing, speech and in severe cases breathing. We see in studies that between 50 to 60 percent of patients with what was at first only an ocular issue may in fact go on to develop generalised disease within two years of the onset of symptoms especially if left untreated. This is why we see close monitoring and early intervention as non optional elements; they play a large role in how the condition plays out over time.
How Do You Treat Myasthenia Gravis in the Eyes?
Treatment for ocular myasthenia gravis is tailored to symptom severity and the likelihood of progression. Several approaches are used, often in combination.
| Treatment | How it helps | Notes |
| Pyridostigmine (Mestinon) | Inhibits the breakdown of acetylcholine at the neuromuscular junction, improving muscle contraction. | Often the first medication tried; helps symptoms but does not modify the underlying disease. |
| Oral corticosteroids (prednisolone) | Suppress the immune response responsible for the antibody attack. | Effective but long-term use carries systemic side effects; dose is gradually tapered once control is achieved. |
| Steroid-sparing immunosuppressants | Azathioprine, mycophenolate mofetil, or other agents used to reduce reliance on steroids. | Takes weeks to months to reach full effect; important for long-term disease control. |
| Thymectomy | Surgical removal of the thymus; has been shown to improve long-term outcomes in certain patient groups, particularly those with thymoma or generalised disease. | Role in purely ocular myasthenia is more debated; discussed case by case. |
| Prism glasses | Can correct double vision by aligning the two images using optical prisms in the spectacle lenses. | Useful as a temporary or long-term aid when diplopia is stable. |
| Ptosis crutches or eyelid props | Spectacle-mounted supports that physically hold the drooping eyelid open. | Non-invasive option for ptosis that is not well controlled medically. |
| Eyelid or strabismus surgery | Considered for stable, non-fluctuating cases where the degree of ptosis or misalignment has been consistent for a long time. | Timing is important surgery during an active fluctuating phase often gives poor outcomes. |
Newer biological treatments including eculizumab and efgartigimod have been approved for generalised myasthenia gravis in some countries and are being studied in ocular disease. These are not yet standard first-line options for purely ocular myasthenia, but they represent an important direction in treatment research.
Eye Care at Vasan Eye Care
At Vasan Eye Care we see patients with ptosis, double vision, or what is to say fluctuating eye muscle weakness and we evaluate them with a structured approach which includes in depth clinical exam, photo documentation of ptosis, and we coordinate with neurology for electrophysiological tests and blood work as indicated.
We provide eye treatments like prism glasses and ptosis management which also includes advice on immunosuppressive therapy in collaboration with neurologists. For patients with stable long term eye findings which make them candidates for surgical correction once the disease is stable we plan oculoplastic and strabismus surgery.
Key Takeaways
Ocular myasthenia gravis which causes variable weakness of the eye and eye movement muscles due to an autoimmune attack at the neuromuscular junction.
The main symptoms are drooping of the eyelid and double vision which tend to worsen with fatigue and improve with rest. It is a real treatable condition which is not just tiredness or aging.
Diagnosis requires blood tests, electrophysiology, and chest imaging to rule out thymus issues.
Treatment includes symptom management with pyridostigmine, immune suppression with steroids and other agents, and optical or surgical support for residual ptosis or double vision.
In about half of patients with pure ocular myasthenia generalized disease may develop which is why early diagnosis and follow up at a dedicated eye specialist hospital is a key part of the long term management.
Frequently Asked Questions
Treatment usually begins with pyridostigmine which improves the signal at nerve and muscle junction. If symptoms do not respond well to that we add in oral corticosteroids to modulate the immune response. In the long term we include steroid sparing immunosuppressants. For persistent double vision we use prism glasses and for stable lid droop we use crutches or go ahead with surgery. Treatment is very much a personalized approach based on the degree of illness and the disease pattern.
It is a large scale issue which presents with droopy eyelids and double vision. In most cases it does not directly cause vision loss, also about half of our patients see it progress to general myasthenia gravis which may include muscles that control swallowing and breathing. That risk of progression is what makes proper diagnosis and follow up so important even when the eyes are the only thing affected.
The primary signs which present are drooping of one or both eyelids and double vision which in large part is noticed at the end of the day or after extensive use of the eyes. That these symptoms improve with rest and fade away with fatigue is a main telling feature. Also some patients report that their eye turns in or out and that they have trouble moving their eye in certain directions.
In most cases we see that. With proper medication, most patients with ocular myasthenia gravis do very well in terms of symptom control. Some achieve full remission. In the case of residual stable issues, we have had success with optical aids and surgery. Treatment does require follow up and in some cases may be long term but in the main what we find is that this is a very manageable condition with the right care at a specialized eye care facility.
References
- Cleveland Clinic – Myasthenia Gravis
https://my.clevelandclinic.org/health/diseases/17252-myasthenia-gravis-mg - Mayo Clinic – Myasthenia Gravis
https://www.mayoclinic.org/diseases-conditions/myasthenia-gravis/symptoms-causes/syc-20352036